NSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,481.80
- Market cap
- ₹70,043 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 39.0×Sector 37.9×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Results Update
Glenmark Pharmaceuticals released its Q2 FY27 press release and MD&A for the quarter ended September 2026. Highlights show India growth and lower North America revenue.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Other employee stock options announcements
All →Zensar Technologies Employee Stock Options
Zensar Technologies allotted 31,440 equity shares to employees on exercise of ESOPs. Paid-up share capital rose to ₹45.55 crore across 22.78 crore shares.
IIFL Finance Employee Stock Options
IIFL Finance allotted 1,97,523 equity shares to eligible employees on exercise of ESOPs, approved by the NRC on 5 November 2026. No cash consideration per share is stated in the filing.
Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care allotted 54,728 equity shares to employees on exercise of ESOP 2022 options. Paid-up capital rose to 31,70,99,111 shares, with no cash consideration stated.
Avenue Supermarts Employee Stock Options
Avenue Supermarts allotted 1,204 equity shares to employees on exercise of ESOP Scheme 2023 options at ₹3,350 per share. Paid-up capital rises to ₹6,523.11 Crore.
- Value
- ₹0.40 Cr
Avenue Supermarts Employee Stock Options
Avenue Supermarts allotted 1,204 equity shares of Rs 10 face value to employees under its ESOP Scheme 2023, lifting paid-up capital to Rs 652.31 Crore. No cash subscription amount or issue price is disclosed.
Vedant Fashions Employee Stock Options
Vedant Fashions reissued forfeited shares through 9,887 equity options granted under its ESOP scheme. The stated issue amount is Rs. 0.50 crore, and paid-up capital is unchanged at Rs. 24.30 crore.